ZIOPHARM Oncology Inc. (ZIOP)

4.53
0.02 0.44
NASDAQ : Health Technology
Prev Close 4.51
Open 4.52
Day Low/High 4.49 / 4.57
52 Wk Low/High 3.33 / 7.00
Volume 148.35K
Avg Volume 1.11M
Exchange NASDAQ
Shares Outstanding 142.40M
Market Cap 618.01M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest Increases 13.4% For ZIOP

Short Interest Increases 13.4% For ZIOP

The most recent short interest data has been released for the 02/15/2018 settlement date, which shows a 4,176,071 share increase in total short interest for ZIOPHARM Oncology Inc , to 35,317,685, an increase of 13.41% since 01/31/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ziopharm Oncology Presents Data On Very Rapid Production Of CAR T Cells At Keystone Symposia Emerging Cellular Therapies: T Cells And Beyond

Ziopharm Oncology Presents Data On Very Rapid Production Of CAR T Cells At Keystone Symposia Emerging Cellular Therapies: T Cells And Beyond

Human CAR+ T cells with membrane-bound IL-15 manufactured in less than two days exhibited anti-tumor activity and persistence in pre-clinical studies

ZIOP: Insiders vs. Shorts

ZIOP: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/12/2018 settlement date, and ZIOPHARM Oncology Inc is one of the most shorted stocks of the Russell 3000, based on 17.77 "days to cover" versus the median component at 4.53. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

First Week of February 2018 Options Trading For ZIOPHARM Oncology (ZIOP)

First Week of February 2018 Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

First Week of July 2018 Options Trading For ZIOPHARM Oncology (ZIOP)

First Week of July 2018 Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the July 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ZIOP: Insiders Vs. Shorts

ZIOP: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2017 settlement date, and ZIOPHARM Oncology Inc is one of the most shorted stocks of the Russell 3000, based on 20.68 "days to cover" versus the median component at 5.18. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week Of December 15th Options Trading For ZIOPHARM Oncology (ZIOP)

First Week Of December 15th Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new December 15th contracts and identified one put and one call contract of particular interest.

ZIOPHARM Oncology Enters Oversold Territory (ZIOP)

ZIOPHARM Oncology Enters Oversold Territory (ZIOP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of ZIOP November 17th Options Trading

First Week of ZIOP November 17th Options Trading

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D- (Sell)